BOSTON, Sept. 27, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:
PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat
cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Marija Zecevic, Ph.D., the Company's Chief Operating Officer, will present at the Cantor Global Healthcare
Conference on Wednesday, October 3, 2018 at 3:25 p.m. ET at the InterContinental New York Barclay.
A live audio webcast of the Cantor Global Healthcare Conference presentation will be available on the Investor Events
page in the Investors & Media section of the Company's website, www.proteostasis.com. A replay of the webcast will be available on the Company's website following the
presentation.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA,
the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. In addition to its
multiple programs in cystic fibrosis, Proteostasis Therapeutics has formed a collaboration with Astellas Pharma,
Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway. For more information,
visit www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the
current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar
expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Examples of forward-looking statements made in this release include, without
limitation, statements regarding expected presentations and expected timing of the initiation of, patient enrollment in, data
from, and the completion of, our clinical studies and cohorts for our clinical programs. Forward-looking statements made in
this release involve substantial risks and uncertainties that could cause actual results to differ materially from those
expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions,
expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the
possibility final or future results from our drug candidate trials (including, without limitation, longer duration studies) do
not achieve positive results or are materially and negatively different from or not indicative of the preliminary results
reported by the Company (noting that these results are based on a small number of patients and small data set), uncertainties
inherent in the execution and completion of clinical trials (including, without limitation, the possibility that
FDA comments delay, change or do not permit trial commencement, or intended label, or the FDA requires us to run
cohorts sequentially or conduct additional cohorts or pre-clinical or clinical studies), in the enrollment of CF patients in our
clinical trials in a competitive clinical environment, in the timing of availability of trial data, in the results of the
clinical trials, in possible adverse events from our trials, in the actions of regulatory agencies, in the endorsement, if any,
by therapeutic development arms of CF patient advocacy groups (and the maintenance thereof), and those set forth in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2018 and our other SEC filings. We assume no
obligation to update or revise any forward-looking statements, whether as a result of new information, future events or
otherwise.
CONTACTS:
Investors:
David Pitts / Claudia Styslinger
Argot Partners
212.600.1902
[email protected] / [email protected]
Media:
David Rosen
Argot Partners
212.600.1902
[email protected]
View original content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-to-present-at-the-cantor-global-healthcare-conference-300719717.html
SOURCE Proteostasis Therapeutics, Inc.